Brief: Biofrontera AG Says In Q3 Generated Between EUR 2.7 And 2.9 Mln From Sales Of Ameluz In USA
09/10/2020 15:47
Oct 9 (Reuters) - Biofrontera AG B8FGn.DE :
* BIOFRONTERA REPORTS PRELIMINARY UNAUDITED SALES REVENUE
FOR THE
THIRD QUARTER OF 2020
* BIOFRONTERA AG - FROM JAN 1 TO SEPT 30, GENERATED PRELIM
UNAUDITED REVENUE OF ABOUT EUR 20.8 TO 21.0 MILLION, UP 9%
* BIOFRONTERA AG - IN Q3 2020, GENERATED BETWEEN EUR 2.7 AND
2.9
MILLION FROM SALES OF AMELUZ® IN USA, COMPARED TO EUR 3.4
MILLION IN Q3 2019
* BIOFRONTERA AG - PRODUCT SALES IN GERMAN MARKET INCREASED
SIGNIFICANTLY COMPARED TO PREVIOUS YEAR
Source text for Eikon: GNX8BBW7m
Further company coverage: B8FGn.DE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biofrontera AG
See all newsBrief: Biofrontera Says Co And Units Have Entered Into An Agreement With Biofrontera Inc About How To Settle Payment Obligations By Biofrontera Inc
Brief: Biofrontera AG Says Legal Dispute On Import In USA Will Result In Revised Outlook
Brief: Biofrontera AG Resolves Capital Increase From Authorized Capital
Brief: Biofrontera AG Says Plans Capital Reduction And Considers Subsequent Capital Increase From Authorized Capital
Brief: Biofrontera AG Says FY 2022 Total Revenue Amounted To EUR 25.7 Million